The latest breakthrough in neuroendocrine cancer treatment comes from the NETTER-2 trial, where Lutetium (177Lu) oxodotreotide, a radio-labeled somatostatin analog, has shown remarkable success in treating high-grade advanced gastroenteropancreatic neuroendocrine...
As many of you will know, Neuroendocrine Cancer UK is a member of INCA (the International Neuroendocrine Cancer Alliance). INCA is the global voice for patients with Neuroendocrine Cancer, with a mission to raise awareness, push for scientific advancements, focus on...
